Intermittent Androgen Suppression: Too Good to be True?
- 1 January 1999
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 33 (203) , 45-49
- https://doi.org/10.1080/003655999750169376
Abstract
The progression of metastatic prostate cancers to an androgen-independent state removes the possibility of further androgen therapy. In response to this, new treatments that do not cause the loss of androgen sensitivity have been sought. Intermittent androgen suppression therapy, an adaptation of the previously used androgen ablation techniques, has shown great promise, comparing favourably with continuous androgen deprivation in pilot studies. It may, therefore, prove to be an excellent treatment, both individually and in combination, although further studies are required.Keywords
This publication has 8 references indexed in Scilit:
- Intermittent androgen suppression for prostate cancer: rationale and clinical experience.European Urology, 1998
- Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancerUrology, 1997
- Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot studyUrology, 1996
- Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer, 1993
- Effect of Suramin on Growth of Androgen-Responsive Mouse Tumor(Shionogi Carcinoma 115) and Its Autonomous Subline(Chiba Subline 2).Endocrinologia Japonica, 1990
- Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold conceptThe Prostate, 1987
- Intermittent endocrine therapy for advanced prostate cancerCancer, 1986
- The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancerThe Prostate, 1984